Table 2.
Patient characteristics depending on the most commonly used induction regimens prior to ASCT and basic information on induction and stem cell mobilization
| Parameter | VAD n = 95 |
VMP n = 93 |
BPV n = 169 |
VD n = 33 |
PAD n = 29 |
VCD n = 70 |
|---|---|---|---|---|---|---|
| Median age, years (range) |
57 (38–70) |
59 (41–71) |
60 (32–75) |
60 (40–73) |
61 (48–71) |
63 (29–72) |
| eGFR (mL/min) | ||||||
| ≥ 60, n (%) | 60 (73) | 73 (80) | 116 (69) | 27 (82) | 23 (79) | 54 (78) |
| 30–59, n (%) | 18 (22) | 16 (18) | 23 (14) | 3 (9) | 4 (15) | 12 (17) |
| 15–29, n (%) | 4 (5) | 1 (1) | 15 (9) | 3 (9) | 2 (7) | 3 (4) |
| < 15, n (%) | 1 (1) | 1 (1) | 15 (9) | 0 | 0 | 1 (1) |
| Unavailable, n | 12 | 2 | 0 | 0 | 0 | 0 |
| Number of cycles median (range) |
4 (2–6) |
2 (1–6) |
2 (1–6) |
5 (2–8) |
3 (1–4) |
4 (2–6) |
| Time to start mobilizationa, days, median (range) |
156 (59–352) |
102 (42–310) |
71 (26–309) |
121 (56–240) |
89 (59–183) |
102 (45–198) |
| CD34+cells (× 106/kg), median (range) |
12.6 (3.3–70.6) |
10.3 (2.5–30.5) |
13.5 (1,7–31) |
14.2 (2.8–25.2) |
6.5 (1–26.7) |
11.9 (3.9–67.1) |
| Number of apheresis, median (range) |
1 (1–3) |
2 (1–4) |
1 (1–4) |
2 (1–3) |
2 (1–3) |
1 (1–3) |
| Time to ASCT, days, median (range)b |
195 (59–517) |
169 (87–363) |
120 (68–431) |
185 (95–330) |
156 (93–328) |
154 (98–286) |
VAD: vincristine, adriamycin and dexamethasone; VMP: bortezomib, melphalan and prednisone, BPV: bendamustine, prednisone and bortezomib; VD: bortezomib and dexamethasone; PAD: bortezomb, adriamycin and dexamethasone; VCD: bortezomid, cyclophosphamide and dexamethasone
aTime from start induction treatment to stem cell mobilization
bTime from start induction treatment to ASCT